CSIMarket
 
Akero Therapeutics Inc   (AKRO)
Other Ticker:  
 
 
Price: $20.5100 $-1.09 -5.046%
Day's High: $21.46 Week Perf: -7.53 %
Day's Low: $ 20.42 30 Day Perf: -25.53 %
Volume (M): 761 52 Wk High: $ 58.38
Volume (M$): $ 15,604 52 Wk Avg: $33.24
Open: $21.41 52 Wk Low: $11.25



 Market Capitalization (Millions $) 1,141
 Shares Outstanding (Millions) 56
 Employees 58
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -120
 Cash Flow (TTM) (Millions $) -105
 Capital Exp. (TTM) (Millions $) 0

Akero Therapeutics Inc
Akero Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases. It was founded in 2017 and is headquartered in South San Francisco, California. The company's lead product candidate, Efruxifermin (EFX), is an engineered analog of fibroblast growth factor 21 (FGF21), a key regulator of metabolism that controls glucose, energy, and lipid homeostasis.

EFX is being developed for the treatment of nonalcoholic steatohepatitis (NASH), a chronic liver disease characterized by fat accumulation in the liver, inflammation, and fibrosis. NASH is a growing public health concern with no approved treatments available. EFX has the potential to address the underlying metabolic dysfunction in NASH patients and reduce liver fat, inflammation, and fibrosis, thereby improving liver and overall metabolic health.

Akero Therapeutics has completed several clinical trials of EFX, including a Phase 2a clinical trial in NASH patients, which showed promising results. The company has also initiated a Phase 2b clinical trial in NASH patients, which is currently ongoing.

In addition to NASH, Akero Therapeutics is exploring the potential of EFX in other metabolic diseases, such as type 2 diabetes and obesity. The company is also conducting research on other FGF analogs and their potential applications in metabolic diseases.

Akero Therapeutics is led by a team of experienced biotech executives and researchers with a proven track record of developing and commercializing successful therapies. The company has formed strategic partnerships with industry leaders, including Amgen and Atlas Venture, to advance the development of EFX and other product candidates.

Overall, Akero Therapeutics is a promising biotech company with a potentially transformative therapy for NASH and other metabolic diseases. The company's innovative approach and experienced leadership team make it an exciting company to watch in the biopharmaceutical industry.


   Company Address: 601 Gateway Boulevard, Suite 350 South San Francisco 94080 CA
   Company Phone Number: 487-6488   Stock Exchange / Ticker: NASDAQ AKRO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares, Marking a Significant Milestone in Advancing Revolutionary Treatments for Metabolic Diseases.

Published Fri, Mar 8 2024 9:02 PM UTC

Akero Therapeutics, Inc. has recently announced the successful closing of its underwritten public offering of common stock, along with the full exercise of underwritersn option to purchase additional shares. This clinical-stage company focuses on developing innovative treatments for patients suffering from serious metabolic diseases, characterized by a high unmet medical nee...

Clinical Study

Efruxifermin: A Promising Breakthrough in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Published Thu, Mar 7 2024 9:01 PM UTC

Non-alcoholic steatohepatitis (NASH) is a progressive liver disease characterized by inflammation and liver cell damage, often leading to fibrosis, cirrhosis, and even hepatocellular carcinoma. With the increasing prevalence of NASH worldwide, there is a pressing need for effective therapeutic interventions to halt or reverse the disease progression. In this article, we disc...

Shares

Akero Therapeutics Raises $300 Million in Public Offering to Revolutionize Treatment for Metabolic Diseases

Published Mon, Mar 4 2024 9:22 PM UTC

Akero Therapeutics Embarks on $300 Million Public Offering as It Advances in the Transformational Treatment of Metabolic Diseases
SOUTH SAN FRANCISCO, Calif., March 04, 2024 - Akero Therapeutics, a leading clinical-stage company specializing in the development of revolutionary therapies for patients suffering from severe metabolic diseases with high unmet medical need, h...

Clinical Study

Akero Therapeutics' EFX Demonstrates Substantial Histological Improvements in Phase 2b HARMONY Study, Providing Hope for NASH Treatment

Published Mon, Mar 4 2024 11:00 AM UTC

Akero Therapeutics Reports Significant Histological Improvements in Phase 2b HARMONY Study at Week 96Akero Therapeutics, a leading biotechnology company, recently released a press release highlighting the encouraging results of their Phase 2b HARMONY study. The study evaluated the efficacy and safety of EFX, the company's investigational drug, in patients with nonalcoholic s...

Clinical Study

Efruxifermin Shows Promising Results in Phase 2b HARMONY Study for Pre-Cirrhotic MASH Patients

Published Thu, Feb 29 2024 1:00 PM UTC

eagerly awaits the release of topline Week 96 results from the Phase 2b HARMONY study, being conducted by Akero Therapeutics. This study focuses on investigating the potential of efruxifermin as a treatment for patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH). An investor webcast has been scheduled on Monday, March 4 at 8:00 a.m. ET to present the highly anti...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com